Agios Appoints Scott Biller, Ph.D., Industry Leader and Drug Developer, as Chief Scientific Officer
Agios Appoints Scott Biller, Ph.D., Industry Leader and Drug Developer, as Chief Scientific Officer
About this item
Full title
Agios Appoints Scott Biller, Ph.D., Industry Leader and Drug Developer, as Chief Scientific Officer
Publisher
New York: Business Wire
Journal title
Business Wire, 2010
Language
English
Formats
Publication information
Publisher
New York: Business Wire
Subjects
More information
Scope and Contents
Contents
Among his other key leadership positions at BMS, Dr. Biller was the Executive Director of Metabolic Diseases Chemistry, with responsibility for discovery programs in hypercholesterolemia and atherosclerosis, diabetes, obesity, osteoporosis and endocrine dysfunctions of the aging population.
Alternative Titles
Full title
Agios Appoints Scott Biller, Ph.D., Industry Leader and Drug Developer, as Chief Scientific Officer
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_wirefeeds_751523613
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_wirefeeds_751523613
How to access this item
Log in as a Library member
